Product Description: Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer[1][2][3][4][5].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346./[2]Wang J, et al Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019 Nov-Dec;11(8):1443-1451./[3]Zhang L, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020 Nov 26;10:594558./[4]Yan Q, et al. Prebiotics Modulate Gut Microbiota-mediated T-cell Immunity to Enhance the Inhibitory Effect of Sintilimab in Lewis Lung Adenocarcinoma Model Mice. Anticancer Agents Med Chem. 2023;23(17):1966-1973./[5]Zhang L, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 2022 Apr 18;10(1):23.
Molecular Weight: N/A
Research Area: Cancer; Inflammation/Immunology
Target: PD-1/PD-L1
English
Deutsch
